[AMENDMENT IN THE NATURE OF A SUBSTITUTE]

September 25, 2002

107TH	CONGRESS
$2\mathrm{D}$	Session

H. R. ____

IN THE HOUSE OF REPRESENTATIVES

Mr.	TAUZIN	introduced	the	following	bill;	which	was	referred	to	the	Comn	nittee
			01	ı				_				

A BILL

To amend title IX of the Public Health Service Act to provide for the improvement of patient safety and to reduce the incidence of events that adversely effect patient safety, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Patient Safety and
- 5 Quality Improvement Act".



1 SEC. 2. FINDINGS AND PURPOSES.

- (a) FINDINGS.—The Congress finds as follows:
- (1) In 1999, the Institute of Medicine released a report entitled "To Err Is Human" that described medical errors as the 8th leading cause of death in the United States, with as many as 98,000 people dying as a result of medical errors each year.
 - (2) To address these deaths and injuries due to medical errors, the health care system must identify and learn from such errors so that systems of care can be improved.
 - (3) Myriad public and private patient safety initiatives have begun. The Quality Interagency Coordination Task Force has recommended steps to improve patient safety that may be taken by each Federal agency involved in health care and activities relating to these steps are ongoing.
 - (4) The Department of Health and Human Services has initiated several patient safety projects. The Joint Commission on Accreditation of Healthcare Organizations issued a patient safety standard that went into effect on July 1, 2001, and the peer review organizations are conducting ongoing studies of clinical performance measurement of care delivered to beneficiaries under the medicare program under title XVIII of the Social Security Act.



1	(5) Several steps can be taken now to improve
2	patient safety. For example, according to the Cen-
3	ters for Disease Control and Prevention, hand wash-
4	ing is the single most important means of preventing
5	the spread of infection. Repeated studies indicate
6	that lack of or improper hand washing still contrib-
7	utes significantly to disease transmission in health
8	care settings. Working with experts from the private
9	sector, the Centers for Disease Control and Preven-
10	tion has drafted "Guidelines for Hand Hygiene in
11	Healthcare Settings" setting forth recommendations
12	to promote improved hand hygiene practices and re-
13	duce transmission of pathogenic microorganisms to
14	patients and personnel in health care settings.
15	(6) According to the Centers for Disease Con-
16	trol and Prevention, nosocomial infections affect ap-
17	proximately 2 million patients annually in acute care
18	facilities in the United States at an estimated direct
19	patient care cost of approximately \$3.5 billion each
20	year.
21	(7) The Congress encourages the continuation
22	and acceleration of private sector efforts to take im-
23	mediate steps to improve patient safety and recog-
24	nizes the need for action in the public sector to com-



plement these efforts.

1	(8) The research on patient safety unequivo-
2	cally calls for a learning environment, where pro-
3	viders will feel safe to report health care errors, in
4	order to improve patient safety.
5	(9) Voluntary data gathering systems are more
6	supportive than mandatory systems in creating the
7	learning environment referred to in paragraph (8) as
8	stated in the Institute of Medicine's report.
9	(10) Promising patient safety reporting systems
10	have been established throughout the United States,
11	and the best ways to structure and use these sys-
12	tems are currently being determined, largely through
13	projects funded by the Agency for Healthcare Re-
14	search and Quality.
15	(11) Many organizations currently collecting
16	patient safety information have expressed a need for
17	protections that will allow them to review protected
18	information so that they may collaborate in the de-
19	velopment and implementation of patient safety im-
20	provement strategies. Currently, the State peer re-
21	view protections provide inadequate conditions to
22	allow the sharing of information to promote patient
23	safety.
24	(12) In 2001, the Institute of Medicine released
25	a report entitled "Crossing the Quality Chasm" that



1	found that the United States health care system
2	does not consistently deliver high-quality care to pa-
3	tients.
4	(b) Purposes.—The purposes of this Act are—
5	(1) to encourage a culture of safety and quality
6	in the United States health care system by providing
7	for a health care errors reporting system that both
8	protects information and improves patient safety
9	and quality of health care; and
10	(2) to ensure accountability by raising stand-
11	ards and expectations for continuous quality im-
12	provements in patient safety through the actions of
13	the Secretary of Health and Human Services.
14	SEC. 3. AMENDMENTS TO PUBLIC HEALTH SERVICE ACT.
15	(a) In General.—Title IX of the Public Health
16	Service Act (42 U.S.C. 299 et seq.) is amended—
17	(1) in section 912(c), by inserting ", in accord-
18	ance with part C," after "The Director shall";
19	(2) by redesignating part C as part D;
20	(3) by redesignating sections 921 through 928,
21	as sections 931 through 938, respectively;
22	(4) in section 938(1) (as so redesignated), by
2223	(4) in section 938(1) (as so redesignated), by striking "921" and inserting "931"; and



1 "PART C—PATIENT SAFETY IMPROVEMENT

2	"SEC	991	DEFINITIONS
_		921.	

3	"In	this	part:

4	"(1) IDENTIFIABLE INFORMATION.—The term
5	'identifiable information' means information that is
6	presented in a form and manner that allows the
7	identification of any provider, patient, or reporter of
8	patient safety work product. With respect to pa-
9	tients, such information includes any individually
10	identifiable health information as that term is de-
11	fined in the regulations promulgated pursuant to
12	section 264(c) of the Health Insurance Portability
13	and Accountability Act of 1996 (Public Law 104–
14	191; 110 Stat. 2033).

"(2) Nonidentifiable information.—The term 'nonidentifiable information' means information that is presented in a form and manner that prevents the identification of any provider, patient, or reporter of patient safety work product. With respect to patients, such information must be de-identified consistent with the regulations promulgated pursuant to section 264(c) of the Health Insurance Portability and Accountability Act of 1996 (Public Law 104–191; 110 Stat. 2033).



25 "(3) Patient safety evaluation system.—
26 The term 'patient safety evaluation system' means a

	·
1	process that involves the collection, management, or
2	analysis of information for submission to or by a pa-
3	tient safety organization.
4	"(4) Patient safety organization.—The
5	term 'patient safety organization' means a private or
6	public organization or component thereof that is cer-
7	tified, through a process to be determined by the
8	Secretary under section 925, to perform each of the
9	following activities:
10	"(A) The conduct, as the organization or
11	component's primary activity, of efforts to im-
12	prove patient safety and the quality of health
13	care delivery.
14	"(B) The collection and analysis of patient
15	safety work product that is submitted by pro-
16	viders.
17	"(C) The development and dissemination
18	of evidence-based information to providers with
19	respect to improving patient safety, such as rec-
20	ommendations, protocols, or information re-
21	garding best practices.
22	"(D) The utilization of patient safety work
23	product to carry out activities limited to those
24	described under this paragraph and for the pur-

poses of encouraging a culture of safety and of



1	providing direct feedback and assistance to pro-
2	viders to effectively minimize patient risk.
3	"(E) The maintenance of confidentiality
4	with respect to identifiable information.
5	"(F) The provision of appropriate security
6	measures with respect to patient safety work
7	product.
8	"(G) The submission of nonidentifiable in-
9	formation to the Agency consistent with stand-
10	ards established by the Secretary under section
11	923(b) for any National Patient Safety Data-
12	base.
13	"(5) Patient safety work product.—
14	"(A) The term 'patient safety work prod-
15	uct' means any document or communication
16	(including any information, report, record,
17	memorandum, analysis, deliberative work, state-
18	ment, or root cause analysis) that—
19	"(i) except as provided in subpara-
20	graph (B), is developed by a provider for
21	the purpose of reporting to a patient safety
22	organization, and is reported to a patient
23	safety organization;
24	"(ii) is created by a patient safety or-
25	ganization; or



1	"(iii) would reveal the deliberations or
2	analytic process of a patient safety evalua-
3	tion system (as defined in paragraph (3)).
4	"(B)(i) Patient safety work product de-
5	scribed in subparagraph (A)(i)—
6	"(I) does not include any separate in-
7	formation described in clause (ii); and
8	"(II) shall not be construed to include
9	such separate information merely by rea-
10	son of inclusion of a copy of the document
11	or communication involved in a submission
12	to, or the fact of submission of such a copy
13	to, a patient safety organization.
14	"(ii) Separate information described in this
15	clause is a document or communication (includ-
16	ing a patient's medical record or any other pa-
17	tient or hospital record) that is developed or
18	maintained, or exists, separately from any pa-
19	tient safety evaluation system.
20	"(C) Information available from sources
21	other than a patient safety work product under
22	this section may be discovered or admitted in a
23	civil or administrative proceeding, if discover-
24	able or admissible under applicable law.
25	"(6) Provider.—The term 'provider' means—



1	"(A) an individual or entity licensed or
2	otherwise authorized under State law to provide
3	health care services, including—
4	"(i) a hospital, nursing facility, com-
5	prehensive outpatient rehabilitation facil-
6	ity, home health agency, and hospice pro-
7	gram;
8	"(ii) a physician, physician assistant
9	nurse practitioner, clinical nurse specialist
10	certified nurse midwife, psychologist, cer-
11	tified social worker, registered dietitian or
12	nutrition professional, physical or occupa-
13	tional therapist, or other individual health
14	care practitioner;
15	"(iii) a pharmacist; and
16	"(iv) a renal dialysis facility, ambula-
17	tory surgical center, pharmacy, physician
18	or health care practitioner's office, long-
19	term care facility, behavioral health resi-
20	dential treatment facility, clinical labora-
21	tory, or community health center; or
22	"(B) any other person or entity specified
23	in regulations by the Secretary after public no-
24	tice and comment.



1	"SEC. 922. PRIVILEGE FOR PATIENT SAFETY WORK PROD-
2	UCT.
3	"(a) Privilege.—Notwithstanding any other provi-
4	sion of law and subject to subsection (c), patient safety
5	work product shall not be—
6	"(1) subject to a civil or administrative sub-
7	poena or order;
8	"(2) subject to discovery in connection with a
9	civil or administrative proceeding;
10	"(3) subject to disclosure pursuant to section
11	552 of title 5, United States Code (commonly known
12	as the Freedom of Information Act), or any other
13	similar Federal or State law;
14	"(4) required to be admitted as evidence or oth-
15	erwise disclosed in any State or Federal civil or ad-
16	ministrative proceeding; or
17	"(5) if the patient safety work product is identi-
18	fiable information and is received by a national ac-
19	creditation organization in its capacity as a patient
20	safety organization—
21	"(A) used by a national accreditation orga-
22	nization in an accreditation action against the
23	provider that reported the information;
24	"(B) shared by such organization with its
25	survey team; or



1	"(C) required as a condition of accredita-
2	tion by a national accreditation association.
3	"(b) Reporter Protection.—
4	"(1) In general.—A provider may not use
5	against an individual in an adverse employment ac-
6	tion described in paragraph (2) the fact that the in-
7	dividual in good faith reported information—
8	"(A) to the provider with the intention of
9	having the information reported to a patient
10	safety organization; or
11	"(B) directly to a patient safety organiza-
12	tion.
13	"(2) Adverse employment action.—For
14	purposes of this subsection, an 'adverse employment
15	action' includes—
16	"(A) the failure to promote an individual
17	or provide any other employment-related benefit
18	for which the individual would otherwise be eli-
19	gible;
20	"(B) an adverse evaluation or decision
21	made in relation to accreditation, certification,
22	credentialing, or licensing of the individual; and
23	"(C) a personnel action that is adverse to
24	the individual concerned.



1	"(3) Remedies.—Any provider that violates
2	this subsection shall be subject to a civil monetary
3	penalty of not more than \$20,000 for each such vio-
4	lation involved. Such penalty shall be imposed and
5	collected in the same manner as civil money pen-
6	alties under subsection (a) of section 1128A of the
7	Social Security Act are imposed and collected.
8	"(c) Disclosures.—Nothing in this section pro-
9	hibits any of the following disclosures:
10	"(1) Voluntary disclosure of nonidentifiable in-
11	formation.
12	"(2) Voluntary disclosure of identifiable infor-
13	mation by a provider or patient safety organization,
14	if such disclosure—
15	"(A) is authorized by the provider for the
16	purposes of improving quality and safety;
17	"(B) is to an entity or person subject to
18	the requirements of section 264(c) of the
19	Health Insurance Portability and Accountability
20	Act of 1996 (Public Law 104–191; 110 Stat.
21	2033), or any regulation promulgated under
22	such section; and
23	"(C) is not in conflict with such section or
24	any regulation promulgated under such section



1	"(3) Disclosure as required by law by a pro-
2	vider to the Food and Drug Administration, or on
3	a voluntary basis by a provider to a federally estab-
4	lished patient safety program, with respect to an Ad-
5	ministration-regulated product or activity for which
6	that entity has responsibility, for the purposes of ac-
7	tivities related to the quality, safety, or effectiveness
8	of such Administration-regulated product or activity.
9	"(4) Disclosures of patient safety work product
10	in accordance with this part by a provider to a pa-
11	tient safety organization.
12	"(d) Effect of Transfer, Disclosure.—The fol-
13	lowing shall not be treated as a waiver of any privilege
14	or protection established under this part:
15	"(1) The transfer of any patient safety work
16	product between a provider and a patient safety or-
17	ganization.
18	"(2) Disclosure of patient safety work product
19	as described in subsection (c).
20	"(3) The unauthorized disclosure of patient
21	safety work product.
22	"(e) Penalty.—
23	"(1) Prohibition.—Except as provided in this
24	part, and subject to paragraphs (2) and (4), it shall
25	be unlawful for any person to disclose patient safety



1	work product in violation of this section, if such dis-
2	closure constitutes a negligent or knowing breach of
3	confidentiality.
4	"(2) Relation to HIPAA.—The penalty
5	under paragraph (3) for a disclosure in violation of
6	paragraph (1) does not apply if the person would be
7	subject to a penalty under section 264(c) of the
8	Health Insurance Portability and Accountability Act
9	of 1996 (Public Law 104–191; 110 Stat. 2033), or
10	any regulation promulgated under such section, for
11	the same disclosure.
12	"(3) Amount.—Any person who violates para-
13	graph (1) shall be subject to a civil monetary penalty
14	of not more than \$10,000 for each such violation in-
15	volved. Such penalty shall be imposed and collected
16	in the same manner as civil money penalties under
17	subsection (a) of section 1128A of the Social Secu-
18	rity Act are imposed and collected.
19	"(4) Subsequent disclosure.—Paragraph
20	(1) applies only to the first person that breaches
21	confidentiality with respect to particular patient
22	safety work product.
23	"(f) RELATION TO HIPAA.—
24	"(1) In general.—For purposes of applying

the regulations promulgated pursuant to section



1	264(c) of the Health Insurance Portability and Ac-
2	countability Act of 1996 (Public Law 104–191; 110
3	Stat. 2033)—
4	"(A) patient safety organizations shall be
5	treated as business associates; and
6	"(B) activities of such organizations de-
7	scribed in section 921(4) in relation to a pro-
8	vider are deemed to be health care operations
9	(as defined in such regulations) of the provider.
10	"(2) Rule of Construction.—Nothing in
11	this section shall be construed to alter or affect the
12	implementation of such regulations or such section
13	264(c).
14	"(g) No Limitation of Other Privileges.—
15	Nothing in this section shall be construed to affect privi-
16	leges, including peer review and confidentiality protec-
17	tions, that are otherwise available under Federal or State
18	laws.
19	"(h) No Limitation on Contracts.—Nothing in
20	this section shall be construed to limit the power of a pro-
21	vider and a patient safety organization, or a patient safety
22	organization and the Agency or any National Patient
23	Safety Database, consistent with the provisions of this Act
24	and other applicable law, to enter into a contract requiring



- greater confidentiality or delegating authority to make an
 authorized disclosure.
- 3 "(i) RELATION TO STATE REPORTING REQUIRE-
- 4 Ments.—Nothing in this part shall be construed as pre-
- 5 empting or otherwise affecting any State law requiring a
- 6 provider to report information, including information de-
- 7 scribed in section 921(5)(B), that is not patient safety
- 8 work product.
- 9 "(j) Continuation of Privilege.—Patient safety
- 10 work product of an organization that is certified as a pa-
- 11 tient safety organization shall continue to be privileged
- 12 and confidential, in accordance with this section, if the or-
- 13 ganization's certification is terminated or revoked or if the
- 14 organization otherwise ceases to qualify as a patient safety
- 15 organization.
- 16 "(k) Reports on Strategies To Improve Pa-
- 17 TIENT SAFETY.—
- 18 "(1) Draft report.—Not later than the date
- that is 18 months after any National Patient Safety
- 20 Database is operational, the Secretary, in consulta-
- 21 tion with the Director, shall prepare a draft report
- on effective strategies for reducing medical errors
- and increasing patient safety. The draft report shall
- include any measure determined appropriate by the
- Secretary to encourage the appropriate use of such



strategies, including use in any federally funded programs. The Secretary shall make the draft report available for public comment and submit the draft report to the Institute of Medicine for review.

"(2) Final report.—Not later than 1 year after the date described in paragraph (1), the Secretary shall submit a final report to the Congress that includes, in an appendix, any findings by the Institute of Medicine concerning research on the strategies discussed in the draft report and any modifications made by the Secretary based on such findings.

13 "SEC. 923. NATIONAL DATABASE.

14 "(a) AUTHORITY.—

"(1) In General.—In conducting activities under this part, the Secretary shall provide for the establishment and maintenance of a database to receive relevant nonidentifiable patient safety work product, and may designate entities to collect relevant nonidentifiable patient safety work product that is voluntarily reported by patient safety organizations upon the request of the Secretary. Any database established or designated under this paragraph may be referred to as a 'National Patient Safety Database'.



1	"(2) Use of Information.—Information re-
2	ported to any National Patient Safety Database
3	shall be used to analyze national and regional statis-
4	tics, including trends and patterns of health care er-
5	rors. The information resulting from such analyses
6	may be included in the annual quality reports pre-
7	pared under section 913(b)(2).
8	"(3) Advisory role.—The Secretary shall
9	provide scientific support to patient safety organiza-
10	tions, including the dissemination of methodologies
11	and evidence-based information related to root
12	causes and quality improvement.
13	"(b) Standards.—In establishing or designating a
14	database under subsection (a)(1), the Secretary shall, in
15	consultation with representatives of patient safety organi-
16	zations, the provider community, and the health informa-
17	tion technology industry, determine common formats for
18	the voluntary reporting of nonidentifiable patient safety
19	work product, including necessary elements, common and
20	consistent definitions, and a standardized computer inter-
21	face for the processing of the work product. To the extent
22	practicable, such standards shall be consistent with the
23	administrative simplification provisions of part C of title
24	XI of the Social Security Act.



1	"(c) Certain Methodologies for Collection.—
2	The Secretary shall ensure that the methodologies for the
3	collection of nonidentifiable patient safety work product
4	for any National Patient Safety Database include the
5	methodologies developed or recommended by the Patient
6	Safety Task Force of the Department of Health and
7	Human Services.
8	"(d) Facilitation of Information Exchange.—
9	To the extent practicable, the Secretary may facilitate the
10	direct link of information between providers and patient
11	safety organizations and between patient safety organiza-
12	tions and any National Patient Safety Database.
13	"(e) Restriction on Transfer.—Only nonidentifi-
14	able information may be transferred to any National Pa-
15	tient Safety Database.
16	"SEC. 924. TECHNICAL ASSISTANCE.
17	"(a) In General.—The Secretary, acting through
18	the Director, may—
19	"(1) provide technical assistance to patient
20	safety organizations, and to States with reporting
21	systems for health care errors; and
22	"(2) provide guidance on the type of data to be
23	voluntarily submitted to any National Patient Safety



Database.

1	"(b) Annual Meetings.—Assistance provided
2	under subsection (a) may include annual meetings for pa-
3	tient safety organizations to discuss methodology, commu-
4	nication, information collection, or privacy concerns.
5	"SEC. 925. CERTIFICATION OF PATIENT SAFETY ORGANIZA-
6	TIONS.
7	"(a) In General.—Not later than 6 months after
8	the date of enactment of the Patient Safety and Quality
9	Improvement Act, the Secretary shall establish a process
10	for certifying patient safety organizations.
11	"(b) Process.—The process established under sub-
12	section (a) shall include the following:
13	"(1) Certification of patient safety organiza-
14	tions by the Secretary or by such other national or
15	State governmental organizations as the Secretary
16	determines appropriate.
17	"(2) If the Secretary allows other governmental
18	organizations to certify patient safety organizations
19	under paragraph (1), the Secretary shall establish a
20	process for approving such organizations. Any such
21	approved organization shall conduct certifications
22	and reviews in accordance with this section.
23	"(3) A review of each certification under para-
24	graph (1) (including a review of compliance with
25	each criterion in this section and any related imple-



1	menting standards as determined by the Secretary
2	through rulemaking) not less often than every 3
3	years, as determined by the Secretary.
4	"(4) Revocation of any such certification by the
5	Secretary or other such governmental organization
6	that issued the certification, upon a showing of
7	cause.
8	"(c) Criteria.—A patient safety organization must
9	meet the following criteria as conditions of certification:
10	"(1) The mission of the patient safety organiza-
11	tion is to conduct activities that are to improve pa-
12	tient safety and the quality of health care delivery
13	and is not in conflict of interest with the providers
14	that contract with the patient safety organization.
15	"(2) The patient safety organization has appro-
16	priately qualified staff, including licensed or certified
17	medical professionals.
18	"(3) The patient safety organization, within any
19	2 year period, contracts with more than 1 provider
20	for the purpose of receiving and reviewing patient
21	safety work product.
22	"(4) The patient safety organization is not a
23	component of a health insurer or other entity that
24	offers a group health plan or health insurance cov-



erage.

1	"(5) The patient safety organization is man-
2	aged, controlled, and operated independently from
3	any provider that contracts with the patient safety
4	organization for reporting patient safety work prod-
5	uct.
6	"(6) To the extent practical and appropriate,
7	the patient safety organization collects patient safety
8	work product from providers in a standardized man-
9	ner that permits valid comparisons of similar cases
10	among similar providers.
11	"(d) Additional Criteria for Component Orga-
12	NIZATIONS.—If a patient safety organization is a compo-
13	nent of another organization, the patient safety organiza-
14	tion must meet the following criteria as conditions of cer-
15	tification:
16	"(1) The patient safety organization maintains
17	patient safety work product separately from the rest
18	of the organization, and establishes appropriate se-
19	curity measures to maintain the confidentiality of
20	the patient safety work product.
21	"(2) The patient safety organization does not
22	make an unauthorized disclosure under this Act of
23	patient safety work product to the rest of the orga-

nization in breach of confidentiality.



1	"(3) The mission of the patient safety organiza-
2	tion does not create a conflict of interest with the
3	rest of the organization.".
4	(b) Authorization of Appropriations.—Section
5	937 of the Public Health Service Act (as redesignated by
6	subsection (a)) is amended by adding at the end the fol-
7	lowing:
8	"(e) Patient Safety and Quality Improve-
9	MENT.—For the purpose of carrying out part C, there are
10	authorized to be appropriated such sums as may be nec-
11	essary for each of the fiscal years 2003 through 2012.".
12	SEC. 4. PROMOTING THE DIFFUSION AND INTEROPER-
10	
13	ABILITY OF INFORMATION TECHNOLOGY SYS-
13 14	TEMS INVOLVED WITH HEALTH CARE DELIV-
14	TEMS INVOLVED WITH HEALTH CARE DELIV-
14 15	TEMS INVOLVED WITH HEALTH CARE DELIVERY.
141516	TEMS INVOLVED WITH HEALTH CARE DELIV- ERY. (a) VOLUNTARY STANDARDS.—
14 15 16 17	TEMS INVOLVED WITH HEALTH CARE DELIVERY. (a) VOLUNTARY STANDARDS.— (1) IN GENERAL.—Not later than 18 months
14 15 16 17 18	TEMS INVOLVED WITH HEALTH CARE DELIVERY. (a) VOLUNTARY STANDARDS.— (1) IN GENERAL.—Not later than 18 months after the date of the enactment of this Act, the Sec-
14 15 16 17 18	ERY. (a) Voluntary Standards.— (1) In General.—Not later than 18 months after the date of the enactment of this Act, the Secretary of Health and Human Services (in this secretary
14 15 16 17 18 19 20	ERY. (a) Voluntary Standards.— (1) In general.—Not later than 18 months after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the "Secretary") shall—
14 15 16 17 18 19 20 21	ERY. (a) Voluntary Standards.— (1) In General.—Not later than 18 months after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the "Secretary") shall— (A) develop or adopt voluntary national
14 15 16 17 18 19 20 21	ERY. (a) Voluntary Standards.— (1) In General.—Not later than 18 months after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the "Secretary") shall— (A) develop or adopt voluntary national standards that promote the interoperability of



1	(B) in developing or adopting such stand-
2	ards, take into account—
3	(i) the ability of such systems to cap-
4	ture and aggregate clinically specific data
5	to enable evidence-based medicine and
6	other applications that promote the elec-
7	tronic exchange of patient medical record
8	information; and
9	(ii) the cost that meeting such stand-
10	ards would have on providing health care
11	in the United States and the increased effi-
12	ciencies in providing such care achieved
13	under the standards; and
14	(C) submit a report to the Congress con-
15	taining recommendations on such standards.
16	(2) Consultation.—In developing or adopting
17	standards under paragraph (1)(A), the Secretary
18	shall consider the recommendations of the National
19	Committee on Vital Health Statistics for the stand-
20	ardization of message formatting, coding, and vocab-
21	ulary for interoperability of information technology
22	systems involved with health care delivery. The Sec-
23	retary shall consult with representatives of the
24	health information technology industry and the pro-



1	vider community who are involved with the develop-
2	ment of interoperability standards.
3	(b) UPDATES.—The Secretary shall provide for the
4	ongoing review and periodic updating of the standards de-
5	veloped under subsection (a).
6	SEC. 5. GRANTS FOR ELECTRONIC PRESCRIPTION PRO-
7	GRAMS.
8	(a) Grants.—
9	(1) IN GENERAL.—The Secretary of Health and
10	Human Services (in this section referred to as the
11	"Secretary") may make grants to qualified practi-
12	tioners for the purpose of establishing electronic pre-
13	scription programs.
14	(2) Matching funds.—
15	(A) IN GENERAL.—With respect to the
16	costs of establishing an electronic prescription
17	program, a condition for the receipt of a grant
18	under paragraph (1) is that the qualified practi-
19	tioner involved agree to make available (directly
20	or through donations from public or private en-
21	tities) non-Federal contributions toward such
22	costs in an amount that is not less than 50 per-
23	cent of such costs.
24	(B) Determination of amount con-
25	TRIBUTED.—Non-Federal contributions re-



	41
1	quired in subparagraph (A) may be in cash or
2	in kind, fairly evaluated, including equipment or
3	services. Amounts provided by the Federal Gov-
4	ernment, or services assisted or subsidized to
5	any significant extent by the Federal Govern-
6	ment, may not be included in determining the
7	amount of such non-Federal contributions.
8	(b) Study.—
9	(1) In General.—The Secretary, acting
10	through the Director of the Agency for Healthcare
11	Research and Quality, shall support a study to as-
12	sess existing scientific evidence regarding the effec-
13	tiveness and cost-effectiveness of the use of elec-
14	tronic prescription programs intended to improve the
15	efficiency of prescription ordering and the safe and
16	effective use of prescription drugs. The study shall
17	address the following:
18	(A) The ability of such programs to reduce
19	medical errors and improve the quality and
20	safety of patient care.
21	(B) The impact of the use of such pro-
22	grams on physicians, pharmacists, and patients,

including such factors as direct and indirect

costs, changes in productivity, and satisfaction.



23

1	(C) The effectiveness of strategies for over-
2	coming barriers to the use of electronic pre-
3	scription programs.
4	(2) Report.—The Secretary shall ensure that,
5	not later than 18 months after the date of the enact-
6	ment of this Act, a report containing the findings of
7	the study under paragraph (1) is submitted to the
8	appropriate committees of the Congress.
9	(3) Dissemination of findings.—The Sec-
10	retary shall disseminate the findings of the study
11	under paragraph (1) to appropriate public and pri-
12	vate entities.
13	(c) DEVELOPMENT OF MODEL.—The Secretary, act-
14	ing through the Director of the Agency for Healthcare Re-
15	search and Quality, may develop an Internet-based mathe-
16	matical model that simulates the cost and effectiveness of
17	electronic prescription programs for qualified practi-
18	tioners. The model may be designed to allow qualified
19	practitioners to estimate, through an interactive interface,
20	the impact of electronic prescribing on their practices, in-
21	cluding the reduction in drug-related health care errors.
22	(d) Definitions.—For purposes of this section:
23	(1) The term 'electronic prescription
24	program'—



1	(A) means a program for the electronic
2	submission of prescriptions to pharmacies or
3	pharmacy benefit managers and the processing
4	of such submissions by pharmacies; and
5	(B) includes the hardware (including com-
6	puters and other electronic devices) and soft-
7	ware programs for the electronic submission of
8	prescriptions to pharmacies, the processing of
9	such submissions by pharmacies, and decision-
10	support programs.
11	(2) The term 'qualified practitioner' means a
12	practitioner licensed by law to administer prescrip-
13	tion drugs.
13 14	tion drugs. SEC. 6. GRANTS TO HOSPITALS AND OTHER HEALTH CARE
14	SEC. 6. GRANTS TO HOSPITALS AND OTHER HEALTH CARE
14 15	SEC. 6. GRANTS TO HOSPITALS AND OTHER HEALTH CARE PROVIDERS FOR INFORMATION TECH-
14151617	SEC. 6. GRANTS TO HOSPITALS AND OTHER HEALTH CARE PROVIDERS FOR INFORMATION TECH- NOLOGIES.
14151617	SEC. 6. GRANTS TO HOSPITALS AND OTHER HEALTH CARE PROVIDERS FOR INFORMATION TECH- NOLOGIES. (a) IN GENERAL.—The Secretary of Health and
14 15 16 17 18	SEC. 6. GRANTS TO HOSPITALS AND OTHER HEALTH CARE PROVIDERS FOR INFORMATION TECH- NOLOGIES. (a) IN GENERAL.—The Secretary of Health and Human Services (in this section referred to as the "Sec-
14 15 16 17 18	SEC. 6. GRANTS TO HOSPITALS AND OTHER HEALTH CARE PROVIDERS FOR INFORMATION TECH- NOLOGIES. (a) IN GENERAL.—The Secretary of Health and Human Services (in this section referred to as the "Sec- retary") shall make grants to hospitals and other health
14 15 16 17 18 19 20	PROVIDERS FOR INFORMATION TECH- NOLOGIES. (a) IN GENERAL.—The Secretary of Health and Human Services (in this section referred to as the "Sec- retary") shall make grants to hospitals and other health care providers (but not more than 1 grant to any 1 hos-
14 15 16 17 18 19 20 21	PROVIDERS FOR INFORMATION TECH- NOLOGIES. (a) IN GENERAL.—The Secretary of Health and Human Services (in this section referred to as the "Secretary") shall make grants to hospitals and other health care providers (but not more than 1 grant to any 1 hospital or provider) to pay the costs of acquiring or imple-



1	(2) to reduce adverse events and health care
2	complications resulting from medication errors.
3	(b) Special Consideration.—In making grants
4	under subsection (a), the Secretary shall give special con-
5	sideration to applicants who seek to promote the following:
6	(1) Interoperability across hospital services or
7	departments using standards developed or adopted
8	by the Secretary under section 4.
9	(2) Electronic communication of patient data
10	across the spectrum of health care delivery.
11	(3) Computerized physician order entry or bar
12	coding applications.
13	(4) Electronic communication of patient data in
14	hospitals that provide services to underserved or low-
15	income populations.
16	(5) Improved clinical decisionmaking through
17	acquisition and implementation of decision-support
18	technologies.
19	(c) CERTAIN GRANT CONDITIONS.—A condition for
20	the receipt of a grant under subsection (a) is that the ap-
21	plicant involved meet the following requirements:
22	(1) The applicant agrees to carry out a pro-
23	gram to measure, analyze, and report patient safety
24	and medical errors at the hospital or other health

care provider involved, to submit to the Secretary a



description of the methodology that will be used, and to have such program in effect as soon as practicable after the application for the grant is approved, without regard to whether information technologies under the grant have been implemented.

- (2) The applicant has arranged for an evaluation that addresses the effectiveness and cost-effectiveness of the information technology for which the grant is provided and its impact on the quality and safety of patient care, submitted the evaluation plan to the Secretary, and received approval from the Secretary of the applicant's methodology.
- (3) The applicant has or is developing a patient safety evaluation system (as that term is defined in section 921 of the Public Health Service Act (as amended by section 3)) for reporting health care errors to a patient safety organization.
- (4) The applicant agrees to provide the Secretary with such information as the Secretary may require regarding the use of funds under this program or its impact.
- (5) The applicant provides assurances satisfactory to the Secretary that any information technology planned, acquired, or implemented with grant



1	funds under this section will be part of an informa-
2	tion program that—
3	(A) carries out the purposes described in
4	subsection (a); and
5	(B) is comprehensive or will be expanded
6	to become comprehensive, regardless of whether
7	Federal assistance is available for such expan-
8	sion.
9	(d) Technical Assistance to Grantees.—The
10	Secretary, acting through the Director of the Agency for
11	Healthcare Research and Quality, shall provide technical
12	assistance to applicants and grantees to ensure the appro-
13	priate evaluation of the information technologies for which
14	grants are awarded under this section, such as—
15	(1) reviewing and providing technical assistance
16	on the applicant's proposed evaluation;
17	(2) developing mechanisms to ensure ongoing
18	communications between grantees and evaluators to
19	facilitate the identification and resolution of prob-
20	lems as they arise, ensure mutual learning, and pro-
21	mote the rapid dissemination of information;
22	(3) reviewing the interim and final reports re-
23	quired under subsection (e); and



1	(4) disseminating evidence-based information in
2	interim and final reports to patient safety organiza-
3	tions, as appropriate.
4	(e) Evaluation Reports by Grantee.—A condi-
5	tion for the receipt of a grant under subsection (a) is that
6	the applicant agree to submit an interim and a final report
7	to the Secretary in accordance with this subsection.
8	(1) Interim report.—Not later than 1 year
9	after the implementation of information technologies
10	under the grant is completed, the applicant will sub-
11	mit an interim report to the Secretary describing the
12	initial effectiveness of such technologies in carrying
13	out the purposes described in subsection (a).
14	(2) Final Report.—Not later than 3 years
15	after the implementation of information technologies
16	under the grant is completed, the applicant will sub-
17	mit a final report to the Secretary describing the ef-
18	fectiveness and cost-effectiveness of such tech-
19	nologies and addressing other issues determined to
20	be important in carrying out the purposes described
21	in subsection (a).
22	(3) Relation to disbursement of grant.—
23	In disbursing a grant under subsection (a), the Sec-
24	retary shall withhold ½ of the grant until the grant-



1	ee submits to the Secretary the report required in
2	paragraph (1).
3	(f) Reports by Secretary.—
4	(1) Interim reports.—
5	(A) In General.—Through the fiscal year
6	preceding the fiscal year in which the final re-
7	port under paragraph (2) is prepared, the Sec-
8	retary shall submit to the Committee on Energy
9	and Commerce of the House of Representatives
10	and the Committee on Health, Education,
11	Labor, and Pensions of the Senate periodic re-
12	ports on the grant program under subsection
13	(a). Such reports shall be submitted not less
14	frequently than once each fiscal year, beginning
15	with fiscal year 2004.
16	(B) Contents.—A report under subpara-
17	graph (A) shall include information on—
18	(i) the number of grants made;
19	(ii) the nature of the projects for
20	which funding is provided under the grant
21	program;
22	(iii) the geographic distribution of
23	grant recipients; and
24	(iv) such other matters as the Sec-
25	retary determines appropriate.



1	(2) Final Report.—Not later than 180 days
2	after the date on which the last of the reports is due
3	under subsection (e)(2), the Secretary shall submit
4	a final report to the committees referred to in para-
5	graph (1)(A) on the grant program under subsection
6	(a), together with such recommendations for legisla-
7	tion and administrative action as the Secretary de-
8	termines appropriate.
9	(g) Definitions.—For purposes of this section:
10	(1) The term "costs", with respect to informa-
11	tion technologies referred to in subsection (a), in-
12	cludes total expenditures incurred for—
13	(A) purchasing, leasing, and installing
14	computer software and hardware, including
15	hand-held computer technologies;
16	(B) making improvements to existing com-
17	puter software and hardware; and
18	(C) purchasing or leasing communications
19	capabilities necessary for clinical data access,
20	storage, and exchange.
21	(2) The term "health care provider" has the
22	same meaning given to the term "provider" in sec-
23	tion 921 of the Public Health Services Act (as
24	amended by this Act).



1	(h) TERMINATION OF GRANT AUTHORITIES.—The
2	authority of the Secretary to make grants under sub-
3	section (a) terminates upon the expiration of fiscal year
4	2011.
5	(i) Matching Funds.—
6	(1) IN GENERAL.—With respect to the costs of
7	a grant to be carried out under this section, such
8	grant may be made only if the applicant agrees to
9	make available (directly or through donations from
10	public or private entities) non-Federal contributions
11	toward such costs in an amount that is not less than
12	50 percent of such costs (\$1 for each \$1 of Federal
13	funds provided in the grant).
14	(2) Determination of amounts contrib-
15	UTED.—Amounts provided by the Federal Govern-
16	ment, or services assisted or subsidized to any sig-
17	nificant extent by the Federal Government, may not
18	be included in determining the amount of such non-
19	Federal contributions.
20	(j) Authorization of Appropriations.—
21	(1) In general.—For the purpose of carrying
22	out this section, there are authorized to be appro-
23	priated such sums as may be necessary for each of

the fiscal years 2003 through 2011.



1	(2) AVAILABILITY.—Amounts appropriated
2	under paragraph (1) remain available for obligation
3	through fiscal year 2011.
4	SEC. 7. REQUIRED USE OF PRODUCT IDENTIFICATION
5	TECHNOLOGY.
6	The Federal Food, Drug, and Cosmetic Act (21
7	U.S.C. 301 et seq.) is amended—
8	(1) in section 502, by adding at the end the fol-
9	lowing:
10	"(u) If it is a drug or biological product, unless it
11	includes a unique product identifier for the drug or bio-
12	logical product as required by regulations under section
13	510(o)."; and
14	(2) in section 510, by adding at the end the fol-
15	lowing:
16	"(o)(1) The Secretary shall issue, and may periodi-
17	cally revise, regulations requiring the manufacturer of any
18	drug or biological product that is subject to regulation by
19	the Food and Drug Administration, or the packager or
20	labeler of a drug or biological product that is subject to
21	regulation by the Food and Drug Administration, to in-
22	clude a unique product identifier on the packaging of the
23	drug or biological product.
24	"(2) For purposes of this subsection, the term

25 'unique product identifier' means an identification that—



1	"(A) is affixed by the manufacturer, labeler, or
2	packager to each drug or biological product de-
3	scribed in paragraph (1) at each packaging level;
4	"(B) uniquely identifies the item and meets the
5	standards required by this section; and
6	"(C) can be read by a scanning device or other
7	technology acceptable to the Secretary.
8	"(3) A unique product identifier required by regula-
9	tions issued or revised under paragraph (1) shall be based
10	on—
11	"(A) the National Drug Code maintained by
12	the Food and Drug Administration;
13	"(B) commercially accepted standards estab-
14	lished by organizations that are accredited by the
15	American National Standards Institute, such as the
16	Health Industry Business Communication Council or
17	the Uniform Code Council; or
18	"(C) other identification formats that the Sec-
19	retary deems appropriate.
20	"(4) The Secretary may, at the Secretary's discre-
21	tion, waive the requirements of this section, or add addi-
22	tional provisions that are necessary to safeguard the pub-
23	lie health.".

